<DOC>
	<DOCNO>NCT00005024</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug granisetron may help prevent nausea vomit patient treated chemotherapy . PURPOSE : Randomized phase III trial compare effectiveness granisetron placebo prevent nausea vomit chemotherapy patient malignant disease .</brief_summary>
	<brief_title>Granisetron Prevent Nausea Vomiting After Chemotherapy Patients With Malignant Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy safety oral granisetron versus placebo prevent nausea vomit 48 hour begin 24 hour administration cyclophosphamide-based carboplatin-based chemotherapy regimens patient malignant disease . OUTLINE : This randomize , double blind , placebo control , parallel , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive oral granisetron day 0 60 minute prior schedule administration IV cyclophosphamide carboplatin ( doxorubicin ) chemotherapy . On day 1 2 , patient receive oral granisetron approximately time day 0 . Arm II : Patients receive oral granisetron day 0 arm I . On day 1 2 , patient receive oral placebo approximately time granisetron tablet take day 0 . Patients follow 5 11 day last dose study medication . PROJECTED ACCRUAL : A total 434 patient ( 217 per arm ) accrue study .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant disease eligible chemotherapy Scheduled receive regimen chemotherapy contain IV cyclophosphamide carboplatin , without chemotherapy agent Cyclophosphamide must give dose 5001,200 mg/m2 Carboplatin must give dose least 300 mg/m2 unless Calvert dose equation ( use target AUC 6 mg/mL/min ) require less 300 mg/m2 Doxorubicin , give , must infuse within period exceed 1 hour Minimum dose base actual body weight Other emetogenic nonemetogenic agent permit included day 0 chemotherapy regimen without restriction dose Emetogenic agent must give part cyclophosphamidebased carboplatinbased regimen day 0 another time within 72 hour period Cyclophosphamide , carboplatin , doxorubicin must first emetogenic agent give No cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) regimen No primary secondary ( metastatic disease ) brain neoplasm : Signs symptom increase intracranial pressure OR Brain metastasis require treatment within 30 day study entry No sign symptoms cerebral edema Symptomatically `` silent '' metastasis allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No unstable medical disorder No known hypersensitivity 5HT3 receptor antagonist At least 1 hour since prior nausea and/or least 24 hour since prior emesis ( i.e. , vomit and/or retch ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior emetogenic chemotherapy Prior nonemetogenic chemotherapy ( dose and/or agent ) allow provide antiemetic agent require nausea emesis result Endocrine therapy : No chronic ( 1 month ) concurrent corticosteroid except replacement maintenance dose 10 mg prednisone equivalent prophylactic pretherapy dexamethasone day 0 Radiotherapy : At least 24 hour since prior radiotherapy abdominal field ( T10L5 ) No concurrent radiotherapy abdominal field ( T10L5 ) Prior concurrent radiotherapy field allow ( e.g. , pelvic irradiation , thoracic irradiation ) Surgery : Not specify Other : At least 30 day 5 halflives ( whichever longer ) since prior investigational drug At least 8 hour since prior short act agent administer procedure ( e.g. , port insertion ) At least 8 hour since prior concurrent benzodiazepine Concurrent narcotic analgesic allow provided receiving least 1 week prior nausea emesis No chronic ( 1 month ) concurrent agent know significant effect emesis ( e.g. , antipsychotic , cannabinoids , metoclopramide , 5HT3 receptor antagonist ) No concurrent prophylactic antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>